Inhaled corticosteroids versus leukotriene receptor antagonists as first-line therapy for mild persistent asthma in children?

Pediatric Asthma, Allergy and Immunology

Volumn 18, Issue 4, 2005, Pages 259-263

  Kelly, H William ^a,b  

^a Department of Pediatrics   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; MONTELUKAST; NITRIC OXIDE; PLACEBO; SALMETEROL XINAFOATE; ZAFIRLUKAST;

ASTHMA; CHILD; CHILDHOOD DISEASE; CHRONIC DISEASE; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG APPROVAL; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HUMAN; INFANT; LUNG FUNCTION TEST; METERED DOSE INHALER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 29144515449     PISSN: 08831874     EISSN: None     Source Type: Journal    
DOI: 10.1089/pai.2005.18.259     Document Type: Review

References (28)

1. National Institutes of Health: National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the diagnosis and management of asthma update on selected topics 2002. J Allergy Clin Immunol 2002; 110:8142-8219.
2. National Institutes of Health: National Heart, Lung, and Blood Institute. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention revised (2002). NHLBI/WHO Workshop Report. Bethesda, MD: NIH publication No. 02-03659); 2002.
3. PDR Electronic Library. Physicians' Desk Reference, 57th ed. Thomson PDR 2003. Release 2003.1A
4. Food and Drug Administration. Guidance for industry: E11 clinical investigation of medicinal products in the pediatric population, www.fda.gov/cder/guidance/index.htm Last accessed June 2005.
5. Medawar PB. In: Advice to a Young Scientist. New York: Harper and Row, 1979.
6. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, leSouef O, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108:E48.
7. van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr Med Res Opin 2005; 21:971-979.
8. Szefler SJ, Eigen H. Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 2002; 109:730-742.
9. Bisgaard H, Gillies J, Groenewald M, Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children. A dose comparison study. Am J Respir Crit Care Med 1999; 160:126-131.
10. Carlsen KC, Stick S, Kamin W, Cirule I, Hughes S, Wixon C. The efficacy and safety of fluticasone propionate in very young children with persistent asthma symptoms. Respir Med 2005; 99:1393-1402.
11. Roorda RJ, Mezei G, Bisgaard H, Maden C. Response of preschool children with asthma symptoms to fluticasone propionate. J Allergy Clin Immunol 2001; 108:540-546.
12. Moeller A, Franklin P, Hall GL, Turner S, Straub D, Wildhaber JH, Stick SM. Fluticasone dipropionate decreases levels of nitric oxide in recurrently wheezy infants. Pediatr Pulmonol 2004; 38:250-255.
13. Straub DA, Moeller A, Minocchieri S, Harnacher J, Sennhauser FH, Hall GL, Wildhaber JH. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J. 2005; 25:289-294.
14. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005; 116:360-369.
15. Ostrom NK, Decotis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, Crim C. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005; 147:213-220.
16. Peroni D, Bodini A, Del Giudice MM, Loiacono A, Baraldi E, Boner AL, Piacentini G. Effect of budesonide and montelukast in asthmatic children exposed to relevant allergens. Allergy 2005; 60:206-210.
17. Caffey LF, Raissy HH, Marshik P, Kelly HW. A crossover comparison of fluticasone propionate and montelukast on inflammatory indices in children with asthma. Pediatr Asthma Allergy Immunol 2005; 18:10-17.
18. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske Jr RF, Strunk RC, Zeiger RS, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Helat G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233-242.
19. 1 is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001; 107:61-67.
20. Baumgartner RA, Martinez G, Edelman JM, Rodriguez Gomez GG, Bernstein M, Bird S, Angner R, Polis A, Dass SB, Lu S, Reiss TF; Montelukast Asthma Group. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur Respir J 2003; 21:123-128.
21. Bukstein DA, Luskin AT, Bernstein A. "Real world" effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 2003; 90:543-549.
22. Allen-Ramey FC, Duong PT, Riedel AA, Markson LE, Weiss KB. Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline. Ann Allergy Asthma Immunol 2004; 93:373-380.
23. Stempel DA, Mauskopf J, McLaughlin T, Yazdani C, Stanford RH. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001; 95:227-234.
24. Orsini L, Limpa-Amara S, Crown WH, Stanford RH, Kamal K. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. Ann Allergy Asthma Immunol 2004; 92:523-529.
25. Carter ER, Ananthakrishnan M. Adherence to montelukast versus inhaled corticosteroids in children with asthma. Pediatr Pulmonol 2003; 36:301-304.
26. Bibi HS, Feigenbaum D, Hessen M, Shoseyov D. Do current protocols adequately prevent airway remodeling in children with mild intermittent asthma? Respir Med 2005; July 23, e-pub ahead of print.
27. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343:1054-1063.
28. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen Y-Z, Ohlsson SV, Ullman A, Lamm CJ, O'Byrne PM; Start Investigators Group. Early intervention with budesonide in mild persistent asthma: A randomized, double-blind trial. Lancet 2003; 361:1071-1076.